Prevention With Ismigen of RTIs in Kids (PIRTIK)
A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Respiratory tract infections (RTIs) are the leading cause of acute disease incidence worldwide that affect people of all ages. They are usually caused by viral pathogens, the most common of which including rhinoviruses, coronaviruses, adenoviruses, respiratory syncytial virus and influenza viruses. Bacterial pathogens can also cause RTIs, but they are less common. Various studies show the seasonality of RTIs. Influenza tends to occur in late autumn and winter, while other RTIs have a much more diffuse occurrence throughout the year. Although RTIs are usually not life-threatening, they significantly decrease quality of life and represent a substantial proportion of healthcare visits, mainly in women and young children, contributing to a financial burden on society.
Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) which is manufactured by mechanical lysis is currently authorized in two EU Member States (MS), Italy and Poland, where Lallemand Pharma Europe is the Marketing Authorization Holder (MAH) as sublingual tablets for the prophylaxis of recurrent RTI in adults. It is authorized in Poland in children from 3 years of age.
On 27 June 2019, the European Medicines Agency (EMA) recommended that bacterial lysates-containing medicinal products authorized for respiratory conditions should only be used for the prevention of recurrent respiratory tract infections, with the exception of pneumonia. This followed a review in which EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases. Although data are limited, the review found some evidence of effectiveness of bacterial lysates in the prevention of recurrent RTI together with a safety profile in line with what is expected for this type of product. The CHMP therefore recommended that use of bacterial lysates for prevention can continue, but the companies must provide further data on safety and effectiveness by Q1 2026 through the conduct of phase IV double-blind, multicenter, RCTs in this indication.
The present study is a Post-Authorization Efficacy Study (PAES) designed to demonstrate that PMBL® sublingual tablet used according to the SmPC instructions can reduce the incidence of respiratory tract infections in children 3 to 12 years old during the fall and winter period when compared to a matched Placebo.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Bernard GOUT, PharmD, PhD
- Número de telefone: +33776583905
- E-mail: bgout@pharmndev.ch
Locais de estudo
-
-
-
Bialystok, Polônia
- Recrutamento
- Bio Zdrowie
-
Bydgoszcz, Polônia
- Recrutamento
- In Vivo Sp. z o.o.
-
Bydgoszcz, Polônia
- Recrutamento
- Vitamed
-
Krakow, Polônia
- Recrutamento
- Centrum Nowoczesnych Terapii
-
Krakow, Polônia
- Ainda não está recrutando
- Comarch Healthcare S.A.
-
Krakow, Polônia
- Recrutamento
- Linden Sp. z o.o. sp.k.
-
Lublin, Polônia
- Recrutamento
- Allergotest
-
Oświęcim, Polônia
- Recrutamento
- Medicome Sp. z o.o.
-
Poznan, Polônia
- Recrutamento
- Med - Polonia
-
Tarnów, Polônia
- Recrutamento
- Alergo-Med Specjalistyczna Przychodnia
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Children of both genders aged from 3 to 12 years.
- Written informed consent obtained from the parents/legally authorized representatives
- Written assent obtained from the subject from 7 years
- Subject presenting with a susceptibility to respiratory tract infections according to the investigator
- No respiratory tract infection within 15 days before the randomization visit
- All girls of childbearing potential have a negative pregnancy urine testing at randomization visit and are informed and their parents as well of the requirement for contraception during the study.
- A cooperative attitude and ability to correct use of PMBL® tablet.
Exclusion Criteria:
- Subject treated with bacterial lysates within the previous 6 months prior to V1 or ongoing treatment.
- Body temperature ≥ 37.5°C at the randomization visit.
- Pregnant/Lactating female or with sexual activity without hormonal contraception, intrauterine device or barrier methods.
- Primary or secondary immunodeficiency, cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, malignancy, endocrinological diseases or other chronic respiratory diseases, except asthma and allergic rhinitis.
- Known sensitivity to the components of study medication.
- Any major surgery within the last 3 months prior to study enrolment or planned to occur within the duration of study.
Treatment with the following medications:
- Injection or oral administration of steroids within 4 weeks prior to study enrolment.
- Previous and/or concomitant immunosuppressants, immunostimulants, allergen-immunotherapy or gamma globulins within 6 months prior to study enrolment.
- Inability to understand or comply with study procedures or with study treatment intake.
- Subject participating in another interventional clinical study at the time of screening visit.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: PMBL® sublingual tablet
Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) is a sublingual tablet marketed by Lallemand Pharma Europe. Each tablet contains:
The posology of Ismigen® for paediatric population (from 3 years of age) is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months. |
3-month period, 10 days per months during the fall-winter
Outros nomes:
|
|
Comparador de Placebo: Placebo
The comparator is a sublingual tablet, indistinguishable from the investigational product. Each tablet of placebo comparator has the same composition as the investigational medicinal product being tested (with the exception of the active substance, which is replaced by glycine (7 mg)). Posology, instructions for use, contraindications, precautions of use and labelling are identical to those for Ismigen®. The posology of Placebo is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months. |
3-month period, 10 days per months during the fall-winter
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The total number of RTIs experienced by each subject throughout the 7-month study period (3-month treatment + 4-month follow-up).
Prazo: Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Rate of Respiratory Tract Infections (RTIs): the number of RTIs experienced by a subject throughout the study (3 month-treatment period and 4 month-follow-up) will be assessed.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean duration in days per RTI during the overall study period.
Prazo: Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Estimated treatment effect from MMRM with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Number of days with respiratory tract infections during the overall study period
Prazo: Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Negative binomial or Poisson regression with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Number of days of antibiotics use during the overall study period
Prazo: Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Estimated incidence rate ratio (IRR) using negative binomial regression (or Poisson if appropriate) with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Total number of workdays lost by parents due to their child's respiratory infections during the overall study period.
Prazo: Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Total number of workdays lost by children's parents due to the child's respiratory infections during the overall study period (cumulative days) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of physician consultations due to RTI or related complications.
Prazo: Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Number of physician consultations due to RTI or related complications during the overall study period (count) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of antibiotic treatments (courses) for a respiratory event during the overall study period.
Prazo: Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Number of antibiotic treatments courses for a respiratory event during the overall study period (count of courses) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of subjects with (serious) adverse event and (serious) adverse drug reaction
Prazo: Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Descriptive statistics: number and proportion of subjects experiencing events by type and severity Number and type of AEs, SAEs, and SARs during the study period
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Andrzej EMERYK, MD, PhD, University Children Hospital, Lublin, Poland
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LPI-2501
- 2025-524212-11-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .